When a patient receives a cancer diagnosis, time is a scarce resource. Yet for many, the first hurdle after diagnosis is not the tumor's biology but a bureaucratic one: prior authorization. Oncologists across the United States report that obtaining insurance approval for chemotherapy drugs adds a median of five days to treatment initiation, and for some regimens the wait stretches longer. Meanwhile, step therapy protocols—which require patients to try cheaper drugs before the prescribed one—remain largely unchallenged, even when clinical guidelines recommend first-line therapies. Utilization management tools like these have become deeply embedded in the U.S. healthcare system, but their impact on patient outcomes and system costs is increasingly questioned.

When Paperwork Delays Treatment

Prior authorization is a process insurers use to require approval before a physician can prescribe certain drugs or procedures. For cancer care, this often means submitting clinical documentation justifying the chosen regimen. A 2023 survey by the American Medical Association found that 93% of physicians reported care delays due to prior authorization, with oncology among the most affected specialties. Oncologists describe spending hours on paperwork, sometimes hiring dedicated staff to manage authorizations.

The delays are not trivial. For aggressive cancers like pancreatic cancer or acute leukemia, the consequences can be severe. A study in JAMA Oncology found that prior authorization delays of seven days or more were associated with a 16% higher risk of death in patients with advanced lung cancer. For early-stage breast cancer, each week of delay in initiating adjuvant chemotherapy has been linked to a 1–2% increase in mortality, according to a 2022 study in the Journal of the National Cancer Institute. Insurers defend the process as a necessary check against inappropriate prescribing and a way to control costs, but the clinical cost of delay is borne entirely by the patient.

Step therapy, also known as fail-first, is a related tool. It requires patients to try one or more lower-cost drugs before the insurer will cover the physician's preferred treatment. For example, a patient with metastatic breast cancer might be required to try tamoxifen before receiving a CDK4/6 inhibitor, even if guidelines list the latter as first-line. Oncologists argue that step therapy ignores individual tumor biology and can waste precious time on ineffective treatments.

Insurers counter that step therapy is evidence-based and mirrors many clinical pathways. However, the evidence base for step therapy in oncology is thin. Most protocols are developed by pharmacy benefit managers (PBMs) in consultation with insurers, not by treating physicians. The result is a one-size-fits-all approach that can delay effective treatment and increase patient distress.

Step Therapy Rarely Faces Clinical Challenge

Despite the potential for harm, step therapy denials are seldom contested. A 2024 analysis by the Kaiser Family Foundation found that fewer than 10% of prior authorization denials are appealed by physicians. The reasons are multifaceted: the appeal process is time-consuming, requires detailed clinical documentation, and often involves multiple phone calls and faxes. Many practices lack the administrative bandwidth to challenge every denial.

When appeals are filed, they succeed roughly 50–60% of the time, according to data from the Centers for Medicare & Medicaid Services (CMS). This suggests that many denials are not clinically justified, yet the low appeal rate means insurers' decisions stand by default. Some states have enacted laws requiring insurers to respond to urgent oncology prior authorization requests within 48 hours, but compliance varies.

Step therapy protocols are even less likely to be challenged. Most patients and physicians accept the fail-first requirement as a condition of coverage, unaware that exceptions can be requested. Even when exceptions are granted, the process can take days or weeks. A 2022 report from the Government Accountability Office found that step therapy exceptions for cancer drugs were approved in about 70% of cases, but the median time to decision was three days—still a delay for aggressive cancers.

The administrative burden falls disproportionately on smaller independent oncology practices. Large hospital systems often have dedicated teams to manage authorizations and appeals, but solo practitioners and small groups may lack resources. This contributes to a two-tier system where patients at well-resourced centers face fewer delays.

The Hidden Cost of Utilization Management

Prior authorization and step therapy are marketed as cost-control measures, but their administrative costs are substantial. A 2020 study in Health Affairs estimated that each prior authorization request costs the healthcare system between $68 and $93 in physician and staff time. Extrapolated to the roughly 1.5 billion requests processed annually, the total cost exceeds $93 billion—more than the entire budget of the National Institutes of Health.

Cancer care accounts for a disproportionate share of these costs. Oncology drugs are among the most expensive, and insurers scrutinize them heavily. But the savings from denying or delaying expensive drugs may be offset by downstream costs. Delayed chemotherapy can lead to disease progression, which in turn increases emergency department visits, hospitalizations, and the need for more intensive—and costly—treatment. A 2021 study in the Journal of Clinical Oncology found that patients who experienced prior authorization delays had 30% higher rates of hospitalization within 30 days of starting treatment.

Financial toxicity also hits patients before treatment begins. Even when insurance eventually approves a drug, patients may face high out-of-pocket costs due to deductibles or coinsurance. Step therapy can compound this by requiring patients to pay for drugs that are ineffective, only to switch later to the prescribed agent. The cumulative effect is that utilization management, intended to reduce spending, may increase overall costs while harming patients.

Insurers argue that without prior authorization and step therapy, drug spending would spiral out of control. They point to data showing that these tools reduce the use of high-cost drugs by 15–20%. However, these savings are often calculated from the insurer's perspective, not the system's. When hospitalizations and lost productivity are factored in, the net effect is less clear.

How Hospital Consolidation Shapes Formularies

The rise of hospital consolidation has changed the landscape of drug pricing and formulary design. Merged health systems negotiate bulk contracts with drug manufacturers and PBMs, often securing rebates in exchange for placing certain drugs on a preferred tier. These rebates are confidential, but they can influence which drugs appear on formularies and which are subject to step therapy.

Step therapy protocols increasingly align with these payer–PBM deals. For instance, a PBM might offer a large rebate on a particular brand-name drug if the insurer requires patients to try a generic first. The result is that step therapy decisions are driven as much by rebate economics as by clinical evidence. Independent oncology practices, which lack negotiating power, often face the most restrictive formularies.

Consolidation also reduces physician autonomy. When a hospital system acquires a community oncology practice, the practice's prescribing patterns may be forced into the system's formulary. A 2023 study in Health Affairs found that physicians in consolidated markets were more likely to report that step therapy interfered with their ability to provide optimal care. Patients in rural areas, who already have limited access to oncology specialists, face even narrower drug choices.

Some experts argue that consolidation can improve care by standardizing protocols and reducing variation. But when standardization is driven by rebate deals rather than evidence, it can undermine the goal of patient-centered care. The tension between cost control and clinical autonomy is at the heart of the step therapy debate.

What the Evidence Says About Outcomes

Despite widespread use, the evidence base for step therapy in oncology is surprisingly weak. A systematic review published in JAMA Oncology in 2023 found no high-quality studies demonstrating that step therapy reduces overall healthcare spending for cancer patients. The few studies that exist are small, retrospective, and often funded by insurers or PBMs. Independent researchers have called for prospective trials comparing step therapy to unrestricted access.

What evidence does exist suggests harm. The same JAMA Oncology review found that step therapy was associated with lower medication adherence and worse quality-of-life scores. Patients on step therapy regimens had higher rates of toxicity, possibly because they spent longer on ineffective treatments before switching. For cancers with multiple effective first-line options, the fail-first approach can mean months of avoidable side effects.

Prior authorization delays have been more rigorously studied. A 2022 study in the Journal of the National Cancer Institute found that each week of delay in initiating adjuvant chemotherapy for breast cancer was associated with a 1–2% increase in mortality. For early-stage lung cancer, delays of more than eight weeks were linked to a 10% higher risk of recurrence. These findings have led some professional societies to issue guidelines recommending that treatment start within 30 days of diagnosis.

Insurers counter that these studies are observational and may not account for confounding factors. They argue that prior authorization prevents the use of ineffective or unnecessarily expensive drugs, and that the net effect on population health is positive. But without robust real-world evidence, the debate remains unresolved. The lack of transparency in formulary decisions makes it difficult for researchers to assess the true impact.

Policy Fixes and Physician-Led Reforms

Several policy proposals aim to reduce the burden of prior authorization and step therapy. In 2024, the Centers for Medicare & Medicaid Services (CMS) proposed a rule requiring Medicare Advantage plans to streamline prior authorization for routinely approved items and to implement electronic submission standards. The rule also would mandate that plans respond to expedited requests within 72 hours for non-urgent and 24 hours for urgent cases. However, the rule has faced pushback from insurers, who argue it would increase administrative costs.

State-level reforms have also gained traction. As of 2025, more than 20 states have passed laws limiting step therapy for cancer drugs, often requiring insurers to grant exceptions within 48 hours for urgent cases. Some states have adopted "gold-card" programs, which exempt physicians who achieve a high rate of prior authorization approval from future requirements. Early data from Texas and Michigan show that gold-card programs reduce turnaround times without increasing drug spending.

The American Society of Clinical Oncology (ASCO) has advocated for automated real-time benefit check tools that integrate with electronic health records. These tools can instantly verify whether a drug is covered and whether step therapy applies, reducing the need for manual prior authorization. A pilot study at the University of Pittsburgh Medical Center found that real-time benefit checks cut prior authorization time by 40% and reduced chemotherapy delays by two days.

Legislative efforts face strong opposition from the insurance lobby, which argues that utilization management is essential to controlling premiums. The trade-off between access and cost is real, but the current system tilts heavily toward cost control with little transparency. Physicians and patient advocates continue to push for reforms that preserve insurers' ability to manage costs while ensuring timely access to evidence-based care.

Why the Status Quo Persists in a High-Income System

Given the evidence of harm, why do prior authorization and step therapy remain entrenched? One reason is financial: insurers profit from formulary rebates and from the administrative fees they charge for processing claims. Utilization management tools also reduce the use of expensive drugs, which directly improves insurers' bottom lines. The savings are passed on to employers and premium payers, creating a constituency that benefits from the status quo.

Physicians, meanwhile, lack the time and staff to challenge every denial. The average oncologist spends 15 hours per week on prior authorization tasks, according to a 2023 survey by ASCO. This is time not spent with patients. Burnout is high, and many doctors accept denials as an inevitable part of practice rather than fight them. This administrative burden, as noted earlier, disproportionately affects smaller practices, but even in large systems, the volume of denials can overwhelm dedicated teams.

Patients rarely see the bureaucratic process behind their prescription. They may not know that a delay was due to prior authorization, or that a step therapy requirement was imposed by their insurer. Shared decision-making, a cornerstone of modern oncology, rarely includes discussions about formulary restrictions. Patients are left to trust that their doctor's recommendation will be covered, only to discover later that it was not.

Systemic inertia favors established cost-control tools. Insurers have used prior authorization and step therapy for decades, and changing these processes would require significant investment in new technology and workflows. Without a clear mandate from regulators or employers, the default is to maintain the current system. However, there are trade-offs. Some argue that easing utilization management could lead to increased use of expensive drugs with marginal benefits, driving up premiums for all. Insurers point to cases where prior authorization has prevented the use of ineffective drugs, such as the withdrawal of high-cost, low-benefit drugs after evidence review. The challenge is distinguishing between necessary oversight and bureaucratic overreach. The evidence suggests that current processes are overly restrictive, but a complete elimination of utilization management could undermine cost control. The path forward likely involves targeted reforms that streamline approvals for evidence-based therapies while retaining scrutiny for drugs with unclear benefit. Until such reforms are implemented, the quiet, persistent barrier to timely cancer care remains largely unchallenged.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult their healthcare providers about treatment options and insurance coverage.